Potential applications of lactic acid bacteria and bacteriocins in anti-mycobacterial therapy

Tuberculosis (TB) is a communicable disease caused by Mycobacterium tuberculosis (M. tuberculosis). WHO estimated that 10.4 million new (incident) TB cases worldwide in year 2016. The increased prevalence of drug resistant strains and side effects associated with the current anti-tubercular drugs ma...

Full description

Bibliographic Details
Published in:Asian Pacific Journal of Tropical Medicine
Main Authors: Anbarasu Sivaraj, Revathy Sundar, Radhakrishnan Manikkam, Krupakar Parthasarathy, Uma Rani, Vanaja Kumar
Format: Article in Journal/Newspaper
Language:English
Published: Wolters Kluwer Medknow Publications 2018
Subjects:
Online Access:https://doi.org/10.4103/1995-7645.240080
https://doaj.org/article/59bafae6482248a6996e0775285d149c
id ftdoajarticles:oai:doaj.org/article:59bafae6482248a6996e0775285d149c
record_format openpolar
spelling ftdoajarticles:oai:doaj.org/article:59bafae6482248a6996e0775285d149c 2023-05-15T15:08:46+02:00 Potential applications of lactic acid bacteria and bacteriocins in anti-mycobacterial therapy Anbarasu Sivaraj Revathy Sundar Radhakrishnan Manikkam Krupakar Parthasarathy Uma Rani Vanaja Kumar 2018-01-01T00:00:00Z https://doi.org/10.4103/1995-7645.240080 https://doaj.org/article/59bafae6482248a6996e0775285d149c EN eng Wolters Kluwer Medknow Publications http://www.apjtm.org/article.asp?issn=1995-7645;year=2018;volume=11;issue=8;spage=453;epage=459;aulast=Sivaraj https://doaj.org/toc/2352-4146 2352-4146 doi:10.4103/1995-7645.240080 https://doaj.org/article/59bafae6482248a6996e0775285d149c Asian Pacific Journal of Tropical Medicine, Vol 11, Iss 8, Pp 453-459 (2018) bacteriocin lactic acid bacteria antimycobacterial peptides tuberculosis immunomodulation hybrid bacteriocin Arctic medicine. Tropical medicine RC955-962 article 2018 ftdoajarticles https://doi.org/10.4103/1995-7645.240080 2022-12-31T02:10:54Z Tuberculosis (TB) is a communicable disease caused by Mycobacterium tuberculosis (M. tuberculosis). WHO estimated that 10.4 million new (incident) TB cases worldwide in year 2016. The increased prevalence of drug resistant strains and side effects associated with the current anti-tubercular drugs make the treatment options more complicated. Hence, there are necessities to identify new drug candidates to fight against various sub-populations of M. tuberculosis with less or no toxicity/side effects and shorter treatment duration. Bacteriocins produced by lactic acid bacteria (LAB) attract attention of researchers because of its “Generally recognized as safe” status. LAB and its bacteriocins possess an effective antimicrobial activity against various bacteria and fungi. Interestingly bacteriocins such as nisin and lacticin 3147 have shown antimycobacterial activity in vitro. As probiotics, LAB plays a vital role in promoting various health benefits including ability to modulate immune response against various infectious diseases. LAB and its metabolic products activate immune system and thereby limiting the M. tuberculosis pathogenesis. The protein and peptide engineering techniques paved the ways to obtain hybrid bacteriocin derivatives from the known peptide sequence of existing bacteriocin. In this review, we focus on the antimycobacterial property and immunomodulatory role of LAB and its metabolic products. Techniques for large scale synthesis of potential bacteriocin with multifunctional activity and enhanced stability are also discussed. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Asian Pacific Journal of Tropical Medicine 11 8 453
institution Open Polar
collection Directory of Open Access Journals: DOAJ Articles
op_collection_id ftdoajarticles
language English
topic bacteriocin
lactic acid bacteria
antimycobacterial peptides
tuberculosis
immunomodulation
hybrid bacteriocin
Arctic medicine. Tropical medicine
RC955-962
spellingShingle bacteriocin
lactic acid bacteria
antimycobacterial peptides
tuberculosis
immunomodulation
hybrid bacteriocin
Arctic medicine. Tropical medicine
RC955-962
Anbarasu Sivaraj
Revathy Sundar
Radhakrishnan Manikkam
Krupakar Parthasarathy
Uma Rani
Vanaja Kumar
Potential applications of lactic acid bacteria and bacteriocins in anti-mycobacterial therapy
topic_facet bacteriocin
lactic acid bacteria
antimycobacterial peptides
tuberculosis
immunomodulation
hybrid bacteriocin
Arctic medicine. Tropical medicine
RC955-962
description Tuberculosis (TB) is a communicable disease caused by Mycobacterium tuberculosis (M. tuberculosis). WHO estimated that 10.4 million new (incident) TB cases worldwide in year 2016. The increased prevalence of drug resistant strains and side effects associated with the current anti-tubercular drugs make the treatment options more complicated. Hence, there are necessities to identify new drug candidates to fight against various sub-populations of M. tuberculosis with less or no toxicity/side effects and shorter treatment duration. Bacteriocins produced by lactic acid bacteria (LAB) attract attention of researchers because of its “Generally recognized as safe” status. LAB and its bacteriocins possess an effective antimicrobial activity against various bacteria and fungi. Interestingly bacteriocins such as nisin and lacticin 3147 have shown antimycobacterial activity in vitro. As probiotics, LAB plays a vital role in promoting various health benefits including ability to modulate immune response against various infectious diseases. LAB and its metabolic products activate immune system and thereby limiting the M. tuberculosis pathogenesis. The protein and peptide engineering techniques paved the ways to obtain hybrid bacteriocin derivatives from the known peptide sequence of existing bacteriocin. In this review, we focus on the antimycobacterial property and immunomodulatory role of LAB and its metabolic products. Techniques for large scale synthesis of potential bacteriocin with multifunctional activity and enhanced stability are also discussed.
format Article in Journal/Newspaper
author Anbarasu Sivaraj
Revathy Sundar
Radhakrishnan Manikkam
Krupakar Parthasarathy
Uma Rani
Vanaja Kumar
author_facet Anbarasu Sivaraj
Revathy Sundar
Radhakrishnan Manikkam
Krupakar Parthasarathy
Uma Rani
Vanaja Kumar
author_sort Anbarasu Sivaraj
title Potential applications of lactic acid bacteria and bacteriocins in anti-mycobacterial therapy
title_short Potential applications of lactic acid bacteria and bacteriocins in anti-mycobacterial therapy
title_full Potential applications of lactic acid bacteria and bacteriocins in anti-mycobacterial therapy
title_fullStr Potential applications of lactic acid bacteria and bacteriocins in anti-mycobacterial therapy
title_full_unstemmed Potential applications of lactic acid bacteria and bacteriocins in anti-mycobacterial therapy
title_sort potential applications of lactic acid bacteria and bacteriocins in anti-mycobacterial therapy
publisher Wolters Kluwer Medknow Publications
publishDate 2018
url https://doi.org/10.4103/1995-7645.240080
https://doaj.org/article/59bafae6482248a6996e0775285d149c
geographic Arctic
geographic_facet Arctic
genre Arctic
genre_facet Arctic
op_source Asian Pacific Journal of Tropical Medicine, Vol 11, Iss 8, Pp 453-459 (2018)
op_relation http://www.apjtm.org/article.asp?issn=1995-7645;year=2018;volume=11;issue=8;spage=453;epage=459;aulast=Sivaraj
https://doaj.org/toc/2352-4146
2352-4146
doi:10.4103/1995-7645.240080
https://doaj.org/article/59bafae6482248a6996e0775285d149c
op_doi https://doi.org/10.4103/1995-7645.240080
container_title Asian Pacific Journal of Tropical Medicine
container_volume 11
container_issue 8
container_start_page 453
_version_ 1766340074164715520